Case reports published in the Journal of Cardiovascular and Interventional Radiology have found that by using the Surefire Infusion System, radioembolization could be successfully performed without the need to protect nearby blood vessels. This is seen as a significant advance that may enable physicians to safely extend liver cancer treatment to patients who were previously deemed untreatable.
None of the three patients, including one who otherwise could not have been treated, suffered complications as a result of the minimally invasive procedure. All were discharged the following day.
“With the protection from reflux afforded by Surefire’s novel, expandable, funnel-shaped tip we performed successful yttrium-90 radioembolization without coiling,” said Maurice van den Bosch, Interventional Radiologist, University Medical Center Utrecht, The Netherlands. “Positron emission tomography-computed tomography (PET-CT) confirmed adequate, efficient biodistribution of the microspheres in targeted liver segments only.”
In recent years, interventional oncology has emerged as a pillar of modern cancer care. In numerous clinical studies, improved patient outcomes have been achieved with embolization therapy and systemic chemotherapy compared to systemic chemotherapy alone.
“We are gratified that our advanced technology enables a broader population of patients to be treated, including those who otherwise may not have received treatment,” said Surefire Medical CEO Jim Chomas. “These case studies add to the rapidly growing body of clinical evidence indicating that the Surefire Infusion System safely, efficiently and precisely delivers therapy. It may contribute not only to enhanced treatment effectiveness, but also to the palliation of cancers to improve quality of life.”